News
ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer
Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.
Friday 30 January 2026
